(4-(2,2,2-三氟乙氧基)吡啶-2-基)甲醇 | 103577-65-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (4-(2,2,2-三氟乙氧基)吡啶-2-基)甲醇
• 英文名称: (4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methanol
• 英文别名: [4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methanol
• CAS: 103577-65-7
• 化学式: C₈H₈F₃NO₂
• 分子量: 207.152
• InChiKey: KALPHRBHKDXGQH-UHFFFAOYSA-N

物化性质

• 沸点：
  255.7±40.0 °C(Predicted)
• 密度：
  1.350±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  42.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (4-(2,2,2-三氟乙氧基)吡啶-2-基)甲醇 在 氯化亚砜 、 sodium methylate 、 间氯过氧苯甲酸 作用下， 以 氯仿 为溶剂， 生成 5-Propoxy-2-[4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethanesulfinyl]-1H-benzoimidazole
  参考文献：
  名称：

  Synthesis of 2-(((4-fluoroalkoxy-2-pyridyl)methyl)sulfinyl)-1H-benzimidazoles as antiulcer agents.

  摘要：

  合成了许多2-[[（4-氟烷氧基-2-吡啶基）甲基]亚磺酰基]-1H-苯并咪唑，并测试了其抗分泌、抗溃疡和细胞保护活性。这些化合物在抗分泌和抗溃疡效能方面大多优于奥美拉唑，尤其是在保护胃黏膜免受乙醇诱导损伤方面。在这些化合物中，2-[[[3-甲基-4-(2,2,2-三氟乙氧基)-2-吡啶基]甲基]亚磺酰基]-1H-苯并咪唑，AG-1749（兰索拉唑）（6f）被选中进行进一步开发和临床评估。

  DOI：

  10.1248/cpb.38.2853
• 作为产物：
  描述：

  Acetic acid 4-(2,2,2-trifluoro-ethoxy)-pyridin-2-ylmethyl ester 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 2.0h， 生成 (4-(2,2,2-三氟乙氧基)吡啶-2-基)甲醇
  参考文献：
  名称：

  2-[（（2-吡啶基甲基）亚磺酰基] -1H-噻吩并[3,4-d]咪唑。一类新型的胃H + / K（+）-ATPase抑制剂。

  摘要：

  合成2-[（（2-吡啶基甲基）亚磺酰基]噻吩并咪唑类化合物，并研究其作为胃H + / K（+）-ATPase的潜在抑制剂。已发现两种可能的噻吩并咪唑系列的[3,4-d]异构体在体外和体内都是有效的胃酸分泌抑制剂。结构活性关系表明，特别是在吡啶部分的4位具有额外的电子要求特性的亲脂性烷氧基，苄氧基和苯氧基取代基与未取代的噻吩并[3,4-d]咪唑结合会导致具有高活性的化合物。良好的化学稳定性。噻吩并[3,4-d]咪唑部分的各种取代方式导致较低的生物活性。选择了七氟丁氧基衍生物萨维拉唑（HOE 731，5d）进行进一步开发，目前正在临床评估中。

  DOI：

  10.1021/jm00081a004

文献信息

• [EN] ANALOGS OF 2-PRALIDOXIME AS ANTIDOTES AGAINST ORGANOPHOSPHORUS NERVE AGENTS<br/>[FR] ANALOGUES DE 2-PRALIDOXIME EN TANT QU'ANTIDOTES CONTRE DES AGENTS NEUROTOXIQUES ORGANOPHOSPHORÉS
  申请人：UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION

  公开号：WO2020027905A3

  公开（公告）日：2020-04-09
• A novel series of 2-pyridyl-containing compounds as lysophosphatidic acid receptor antagonists: development of a nonhydrolyzable LPA3 receptor-selective antagonist
  作者：Brian H Heasley、Renata Jarosz、Karen M Carter、S Jenny Van、Kevin R Lynch、Timothy L Macdonald

  DOI：10.1016/j.bmcl.2004.05.023

  日期：2004.8

  A recently reported dual LPA(1)/LPA(3) receptor antagonist (1) has been modified so as to modulate the basicity, sterics, and dipole moment of the 2-pyridyl moiety. Additionally, the implications of installing nonhydrolyzable phosphate head group isosteres with regard to antagonist potency and selectivity at LPA receptors is described. This study has resulted in the development of the first nonhydrolyzable and presumably phosphatase-resistant LPA(3)-selective antagonist reported to date. (C) 2004 Elsevier Ltd. All rights reserved.
• Synthesis and structure–activity relationships of tyrosine-based inhibitors of autotaxin (ATX)
  作者：James E. East、Andrew J. Kennedy、Jose L. Tomsig、Alexandra R. De Leon、Kevin R. Lynch、Timothy L. Macdonald

  DOI：10.1016/j.bmcl.2010.09.030

  日期：2010.12

  Autotaxin (ATX) is a secreted soluble enzyme that generates lysophosphatidic acid (LPA) through its lysophospholipase D activity. Because of LPA's role in neoplastic diseases, ATX is an attractive therapeutic target due to its involvement in LPA biosynthesis. Here we describe the SAR of ATX inhibitor, VPC8a202, and apply this SAR knowledge towards developing a high potency inhibitor. We found that electron density in the pyridine region greatly influences activity of our inhibitors at ATX. (C) 2010 Elsevier Ltd. All rights reserved.
• KUBO, KEIJI;ODA, KATSUAKI;KANEKO, TATSUHIKO;SATOH, HIROSHI;NOHARA, AKIRA, CHEM. AND PHARM. BULL. , 38,(1990) N0, C. 2853-2858
  作者：KUBO, KEIJI、ODA, KATSUAKI、KANEKO, TATSUHIKO、SATOH, HIROSHI、NOHARA, AKIRA

  DOI：——

  日期：——
• Analogs of 2-Pralidoxime as Antidotes Against Organophosphorus Nerve Agents
  申请人：University of Pittsburgh - Of the Commonwealth System of Higher Education

  公开号：US20210317084A1

  公开（公告）日：2021-10-14

  Provided herein are compounds useful in treating exposure to an organophosphorus compound, such as a nerve agent, pesticide, or, generally, an acetylcholinesterase inhibitor, such as sarin. Compositions, e.g. pharmaceutical compositions or dosage forms, comprising the compounds also are provided herein. Methods of treating a patient exposed to a nerve agent, pesticide, or, generally, an acetylcholinesterase inhibitor, e.g., an organophosphorus compound, such as sarin, also are provided.